In the evolving landscape of pharmaceutical innovation, the demand for effective antiviral treatments has surged dramatically. One of the most widely recognized molecules in this category is Nirmatrelvir, a protease inhibitor designed to combat viral infections, particularly SARS-CoV-2. Bio-synth stands at the forefront of this movement, committed